Objective
to compare the clinical outcome of the Supraflex stent with Xience stent (everolimus-eluting stent)
Study
prospective, randomised, single-blind, multicentre, non inferiority study (margin 4.0%)
Population
all-comers
Endpoints
composite of cardiac death, target-vessel MI or clinically indicated target-lesion revascularisation at 1 year
Conclusion
the Supraflex stent was non-inferior compared to Xience stent at 12 months in all-comer population
Zaman et al. Lancet 2019;393:987-97